Seed treatment suspending agent containing metalaxyl-M and application thereof

Abstract

The invention belongs to the technical field of agricultural pesticides, and particularly relates to a seed treatment suspending agent containing metalaxyl-M and application. The seed treatment suspending agent comprises the following components in percentage by weight: 1.5-60% of an active component, 1-20% of a wetting dispersant, 0-5% of a grinding aid, 1-10% of an anti-freezing agent, 0.01-2% of a thickening agent, 1-10% of a film-forming agent, 5-20% of warning coloration and the balance of deionized water, wherein metalaxyl-M is contained in the active component. According to the seed treatment suspending agent disclosed by the invention, the problems that the metalaxyl-M liquid raw medicine is difficult to disperse and wrap a solid raw medicine in the preparation process of the seed treatment suspending agent and is adhered to sanding equipment and the sanding efficiency of the solid raw medicine is reduced are effectively solved through the matching combination and reasonable proportioning of the wetting dispersant, the suspension rate of a sample is improved, and the viscosity increase after heat storage is effectively controlled. The seed treatment suspending agent disclosed by the invention is excellent in performance index and good in physical stability.

Description

Technical Field

[0001] This invention belongs to the field of agricultural pesticide technology, specifically relating to a seed treatment suspension containing metalaxyl and its application. Background Technology

[0002] Currently available single-component seed treatment agents often suffer from narrow control spectra and the development of drug resistance when facing complex pathogen infections. This leads to increased dosage, reduced efficacy, and shorter duration of action, which is detrimental to sustainable environmental development. Therefore, developing a novel seed treatment suspension that rationally combines fungicides with different mechanisms of action to improve control efficacy and stability is of significant practical importance.

[0003] Metalaxyl is a highly effective systemic fungicide with strong bactericidal and fungal growth-inhibiting capabilities. It is rapidly absorbed by plant seeds, roots, and leaves and translocated upwards within the plant. Its mechanism of action primarily involves inhibiting RNA biosynthesis, thereby preventing fungal sporulation and inhibiting mycelial growth, ultimately leading to pathogen death. Methoxyacrylate fungicides are characterized by a broad fungicidal spectrum, high activity, low dosage, and a unique mechanism of action. They achieve their bactericidal purpose by inhibiting the respiration of pathogenic cells and interfering with energy synthesis. Triazole fungicides can inhibit the biosynthesis of ergosterol in pathogenic fungi and disrupt cell membrane integrity, showing significant control efficacy against diseases caused by various higher fungi.

[0004] However, in reality, when using metalaxyl and other solid technical materials as active ingredients to prepare seed treatment suspensions, metalaxyl, being a liquid oily technical material, has high interfacial tension with the aqueous phase, making it difficult to spontaneously disperse into fine droplets. Furthermore, the oil phase of metalaxyl easily coats solid particles, preventing other solid technical materials from dispersing and causing them to adhere to the milling media and equipment, thus hindering suspension preparation. This adhesion problem is particularly pronounced when the metalaxyl content in the formulation is high. In addition, the oily droplets formed after emulsification or grinding of metalaxyl lack the rigid structure of solid particles on their surface, interacting with and coating them. Once the solid particles are coated by the oil phase, the dispersant is difficult to adsorb onto the surface, leading to particle agglomeration and severely affecting the milling effect. Moreover, the reduced interparticle friction after the solid particles are coated by the oil phase further decreases milling efficiency. Meanwhile, the complex suspension system prepared from liquid oily technical material and solid technical material is easily affected by temperature. After heat storage, the collision frequency between droplets increases, the emulsifier may fall off from the oil-water interface, leading to droplet aggregation, decreased adsorption stability of dispersant, and increased particle size. Ultimately, this results in the problem of increased viscosity of the sample after heat storage, which seriously affects the state and quality of the sample.

[0005] Patent CN117981748A discloses a seed treatment suspension containing metalaxyl, cymoxanil, and fludioxonil, with adjuvants including sodium dodecylbenzenesulfonate, sodium lignosulfonate, gelatin, and ethylene glycol, but does not address the issue of metalaxyl technical adhering to solid particles. Patent CN119096980A discloses a seed treatment agent containing difenoconazole, metalaxyl, and pyraclostrobin and its application, with adjuvants including Morwet D-425, NNO, calcium lignosulfonate, and Atlox4913, but also does not address or solve the problem of metalaxyl technical adhering to solid particles. Patent CN119744851A discloses a suspension seed coating agent containing thifluzamide, thiamethoxam, and metalaxyl, and its application; CN113180054A discloses a seed treatment suspension agent containing metalaxyl, thifluzamide, and azoxystrobin, and its preparation method and application; CN118892127A discloses a seed coating agent composition containing metalaxyl, fludioxonil, and azoxystrobin, and its application. None of the above patents address the problems existing in the preparation process of metalaxyl technical material.

[0006] Currently available literature on suspensions containing metalaxyl and seed treatment suspensions does not address the problems encountered in the preparation process, nor are there any technical reports on solutions to these problems. Therefore, this study addresses the issues of metalaxyl liquid technical material being difficult to disperse and encapsulate solid technical material during the preparation of its seed treatment suspension, as well as the reduced efficiency of sand milling of solid technical material, by using specific combinations and reasonable proportions of wetting and dispersing agents. Summary of the Invention

[0007] The purpose of this invention is to provide a seed treatment suspension containing metalaxyl and its application.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0009] A seed treatment suspension containing metalaxyl, wherein the seed treatment suspension comprises, by weight percentage, 1.5-60% active ingredient, 1-20% wetting and dispersing agent, 0-5% grinding aid, 1-10% antifreeze agent, 0.01-2% thickener, 1-10% film-forming agent, 5-20% warning color, and deionized water to make up the difference; wherein the active ingredient contains metalaxyl.

[0010] The active ingredients are metalaxyl, compound A, and compound B; wherein compound A is a methoxyacrylate fungicide, and compound B is a triazole fungicide.

[0011] Compound A is selected from tebuconazole (A1), azoxystrobin (A2), or pyraclostrobin (A3); compound B is selected from tebuconazole (B1), prothioconazole (B2), or tebuconazole (B3).

[0012] The seed treatment suspension, by weight percentage, contains 1-10% metalaxyl, 0.5%-10% compound A, 1-10% compound B, 3-15% wetting and dispersing agent, 0.5-5% grinding aid, 4-8% antifreeze, 0.1-2% thickener, 3-6% film-forming agent, 10-15% warning color, and deionized water to make up the difference.

[0013] The wetting and dispersing agent is a block polyether, a polycarboxylate, or a sulfonate; wherein the block polyether, polycarboxylate, and sulfonate account for 1-8%, 1-5%, and 1-4% of the weight of the wetting and dispersing agent, respectively.

[0014] In the wetting and dispersing agent, the weight percentages of block polyethers, polycarboxylate salts, and sulfonates are 2-5%, 2-4%, and 1-3% respectively.

[0015] The block polyether additives have an EO / PO arrangement of EO-PO-EO type and an HLB value between 10 and 16 (e.g., Winst5503, Ethylan NS-500LQ, DOWFAX™ D800, ULTREASURF 8070, TENSIOFIX 96DB08, DOWFAX™ D865, Atlas G-5002L, Genapol PF 40, Genapol 10500, Synergen 848, Pluronic PE6400, YUS-5050PB, SD-208, etc.).

[0016] The polycarboxylate (e.g., DS5518, SP-27001, DOWFAXTM D305, ULTREASURF7023A, DS733, DOWFAX™ D205, DS707, WINST 3682, Dispersogen ACP 120, TENSIOFIX AMS303, Agrilan 755, WINST 3796, SD-816, etc.);

[0017] The sulfonates (e.g., YUS-TXC, YUS-SXC, YUS-A51G, ... DS569, MORWET D425, SP-3259, Winst 1130L, etc.

[0018] The grinding aid is one or more of titanium dioxide, silica, organobentonite, and fumed silica.

[0019] The antifreeze is one or more of ethylene glycol, propylene glycol, glycerol, urea, ammonium sulfate, and sodium sulfate.

[0020] The thickener is one or more of xanthan gum, gelatin, gum arabic, polyvinyl acetate, polyvinylpyrrolidone, magnesium aluminum silicate, polyvinyl alcohol, sodium carboxymethyl cellulose, sodium polyacrylate, and sodium alginate.

[0021] The film-forming agent is one or more of the following: polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyvinyl acetate, polyvinylpyrrolidone (PVP), acrylic resin polymer, polyurethane modified nitrocellulose, polysaccharide polymers, and cellulose derivatives.

[0022] The warning agent may include dyes, pigments (including color powder and color paste), etc.

[0023] A seed treatment suspension containing metalaxyl, the seed treatment suspension being used as a seed coating for crops.

[0024] The application of the seed treatment suspension as a seed coating for the prevention and control of fungal diseases in crops.

[0025] Advantages of this invention:

[0026] This invention combines three fungicides with different mechanisms of action: metalaxyl, compound A (tebuconazole, pyraclostrobin, pyraclostrobin) and compound B (tebuconazole, prothioconazole, tebuconazole). By combining specific types of wetting and dispersing agents and using reasonable proportions, it effectively solves the key problems in the preparation of suspensions from the oily metalaxyl technical material.

[0027] In this invention, the block polyether adjuvant in the specific wetting and dispersing agent of the suspension contains a unique EO-PO-EO triblock structure. The methyl group of the PO chain effectively binds to the fatty chain / benzene ring of metalaxyl through van der Waals forces, while the EO chain binds to water molecules through hydrogen bonds, resulting in directional adsorption at the oil-water interface. This significantly reduces the interfacial tension between the oily active ingredient and the aqueous phase. By screening for a suitable EO / PO ratio (HLB value of 10-16), the appropriate hydrophilic and lipophilic properties effectively solve the problem of metalaxyl's difficulty in dispersing in water. Simultaneously, the sulfonate anionic adjuvant further enhances the dispersion of metalaxyl through electrostatic repulsion of sulfonic acid groups, π-π interactions of alkyl / phenyl groups, and synergistic effects of hydrogen bonding. Furthermore, the carboxyl groups in the polycarboxylate adjuvant molecules can be firmly adsorbed onto the surface of solid active ingredient particles through electrostatic interactions, forming a stable adsorption layer; the hydrophilic segments extend into the aqueous phase, creating a steric hindrance effect, avoiding the aggregation of triazole compounds due to their electronegativity during suspension preparation. It can be seen that by using a specific combination of wetting and dispersing agents, the composite enhancement of the interfacial adsorption layer and the electrostatic-spatial composite stability are achieved through synergistic effects, which can promote dispersion, resist sedimentation and agglomeration, and inhibit Austere ripening. Detailed Implementation

[0028] The following specific embodiments are used to further illustrate the present invention. The present invention includes, but is not limited to, these examples. Methods well known to those skilled in the art are all included within the scope of the present invention.

[0029] For complex suspension systems containing both oily droplets and solid particles, this invention prepares a seed treatment suspension containing metalaxyl. This seed treatment suspension effectively solves the problem of metalaxyl liquid technical material being difficult to disperse and encapsulate solid technical material during the preparation of the seed treatment suspension, leading to adhesion to sand milling equipment and reduced milling efficiency. Simultaneously, it ensures good physicochemical properties and physical stability, facilitating storage and use. Through the rational combination of three fungicides with different mechanisms of action, the control spectrum is effectively broadened, and the dosage of single components is reduced. This seed treatment suspension is used for seed coating, controlling both seed-borne and soil-borne diseases, thus addressing disease control from the crop seed level. This invention primarily and effectively solves the compatibility problem of three fungicides with different mechanisms of action, namely, the problem of metalaxyl oil technical material encapsulating solid technical material, causing poor dispersion, adhesion to sand milling equipment, and reduced milling efficiency.

[0030] All percentages in the formulation are by weight, and the active ingredient is calculated based on its effective content. All active ingredients and excipients used were commercially available.

[0031] The adjuvant system in this invention can improve the product suspension rate and effectively control the viscosity increase problem after heat storage. The seed treatment suspension agent of this invention has excellent performance indicators and good physical stability.

[0032] Formulation Examples

[0033] Example 1-1: A 2.5% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components by weight percentage: metalaxyl 1%, tebufenozide 0.5%, tebufenozide 1%, ULTREASURF 8070 2%, DS5518 2%, YUS-TXC 1%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.22%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R12 15%, Deionized water to make up.

[0034] Preparation method: Wet sand milling method is used. According to the type and amount of each component in the formula, the active ingredients and auxiliary components (excluding antifreeze, film-forming agent, and warning color) are accurately weighed according to the stated ratio. Deionized water is added to bring the total to 45%, and then homogenized and dispersed in a high-speed shear disperser. Shearing is performed at a shear rate of 14000 r / min for 5 min to obtain a mixture. The mixture is then added to a sand mill and ground to a particle size D. 90 <3μm, the seed treatment suspension is obtained. Filter, and finally add antifreeze, film-forming agent, warning color, and deionized water to make up the difference. Homogenize and stir until evenly mixed, then discharge to obtain the final product.

[0035] Examples 1-2: A 2.5% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components by weight percentage: metalaxyl 1%, tebufenozide 0.5%, tebufenozide 1%, ULTREASURF 8070 2%, DS5518 2%, YUS-TXC 1%, titanium dioxide 2%, magnesium aluminum silicate 1.0%, xanthan gum 0.22%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0036] Preparation method: Same as in Example 1-1.

[0037] Example 2-1: A 4.2% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 1.4%, tebufenozide 0.5%, thiamethoxam 2.3%, Winst5503 2%, DS5518 2%, YUS-TXC 1%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.20%, Ethylene glycol 5%, Film-forming agent PVP / VA 645%, Warning color JH-R12 15%, Deionized water to make up.

[0038] Preparation method: Same as in Example 1-1.

[0039] Example 2-2: A 4.2% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 1.4%, tebufenozide 0.5%, thiamethoxam 2.3%, Winst5503 2%, DS5518 2%, YUS-TXC 1%, titanium dioxide 2%, magnesium aluminum silicate 1.0%, xanthan gum 0.20%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0040] Preparation method: Same as in Example 1-1.

[0041] Example 3-1: 9% Metalaxyl·Enoxaflutole·Syzoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Syzoxystrobin 3%, Ethylan NS-500LQ 3%, SP-2700 12%, YUS-TXC 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0042] Preparation method: Wet sand milling method is used. According to the type and amount of each component in the formula, the active ingredients and auxiliary components (excluding antifreeze, film-forming agent, and warning color) are accurately weighed according to the stated ratio. Deionized water is added to bring the total to 50%, and then homogenized and dispersed in a high-speed shear disperser. Shearing is performed at a shear rate of 14000 r / min for 5 min to obtain a mixture. The mixture is then added to a sand mill and ground to a particle size D. 90 <3μm, the seed treatment suspension is obtained. Filter, and finally add antifreeze, film-forming agent, warning color, and deionized water to make up the difference. Homogenize and stir until evenly mixed, then discharge to obtain the final product.

[0043] Example 3-2: 9% Metalaxyl·Enoxaflutole·Syzoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Syzoxystrobin 3%, Ethylan NS-500LQ 3%, SP-2700 12%, YUS-TXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0044] Preparation method: Same as in Example 2-1.

[0045] Example 4-1: 30% Metalaxyl·Enoxaflutole·Syzoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Syzoxystrobin 10%, DOWFAX™ D800 4%, DOWFAXTMD305 3%, YUS-TXC 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0046] Preparation method: Wet sand milling method is used. According to the type and amount of each component in the formula, the active ingredient and auxiliary components (excluding antifreeze, film-forming agent, and warning color) are accurately weighed according to the stated ratio. Deionized water is added to bring the volume to 75%, and then homogenized and dispersed in a high-speed shear disperser at a shear rate of 14000 r / min for 5 min to obtain a mixture. The mixture is then added to a sand mill and ground until the particle size D90 < 3 μm to obtain the seed treatment suspension. After filtration, antifreeze, film-forming agent, and warning color are added, and deionized water is added to bring the volume to a final volume. The mixture is then homogenized and stirred until uniformly mixed before being discharged to obtain the final product.

[0047] Example 4-2: 30% Metalaxyl·Enoxaflutole·Syzoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Syzoxystrobin 10%, DOWFAX™ D800 4%, DOWFAXTMD305 3%, YUS-TXC 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0048] Preparation method: Same as in Example 3-1.

[0049] Example 5-1: A 2.5% metalaxyl-methyl·tebuconazole·prothiophanate-methyl seed treatment suspension, comprising the following components by weight percentage: metalaxyl 1%, tebuconazole 0.5%, prothiophanate-methyl 1%, ULTREASURF 8070 2%, ULTREASURF 7023A 2%, YUS-SXC 1%, magnesium aluminum silicate 1.0%, xanthan gum 0.25%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R121 5%, and deionized water to make up.

[0050] Preparation method: Same as in Example 1-1.

[0051] Example 5-2: 2.5% Metalaxyl·Enoxaflutole·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Enoxaflutole 0.5%, Prothioconazole 1%, ULTREASURF 8070 2%, ULTREASURF 7023A 2%, YUS-SXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 1.0%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0052] Preparation method: Same as in Example 1-1.

[0053] Example 6-1: A 9% metalaxyl-methyl·tebuconazole·prothioconazole seed treatment suspension, comprising the following components in weight percentage: metalaxyl 3%, tebuconazole 3%, prothioconazole 3%, TENSIOFIX 96DB08 2%, DS733 2%, YUS-SXC 1%, Magnesium aluminum silicate 0.8%, Xanthan gum 0.2%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R12 15%, Deionized water to make up.

[0054] Preparation method: Same as in Example 2-1.

[0055] Example 6-2: A 9% metalaxyl-mancozeb-propiconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl 3%, propiconazole 3%, tebuconazole 3%, TENSIOFIX 96DB08 2%. DS733 2%, YUS-SXC 1%, titanium dioxide 2%, magnesium aluminum silicate 0.8%, xanthan gum 0.2%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0056] Preparation method: Same as in Example 2-1.

[0057] Example 7-1: 30% Metalaxyl·Enoxaflutole·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Prothioconazole 10%, DOWFAX™ D865 4%, DOWFAX™ D205 3%, YUS-SXC 2%, Magnesium Aluminum Silicate 0.4%, Xanthan Gum 0.08%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0058] Preparation method: Same as in Example 3-1.

[0059] Example 7-2: 30% Metalaxyl·Enoxaflutole·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Prothioconazole 10%, DOWFAX™ D865 4%, DOWFAX™ D205 3%, YUS-SXC 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.4%, Xanthan Gum 0.08%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0060] Preparation method: Same as in Example 3-1.

[0061] Example 8-1: A 2.5% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components in weight percentage: metalaxyl 1%, tebufenozide 0.5%, tebufenozide 1%, Atlas G-5002L 2%, DS707 2%, YUS-A51G 1%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.25%, Ethylene glycol 5%, Film-forming agent PVP / VA 645%, Warning color JH-R12 15%, Deionized water to make up.

[0062] Preparation method: Same as in Example 1-1.

[0063] Example 8-2: A 2.5% metalaxyl-mancozeb-tebufenozide seed treatment suspension, comprising the following components in weight percentage: metalaxyl 1%, tebufenozide 0.5%, tebufenozide 1%, Atlas G-5002L 2%, DS707 2%, YUS-A51G 1%, titanium dioxide 2%, magnesium aluminum silicate 1.0%, xanthan gum 0.25%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0064] Preparation method: Same as in Example 1-1.

[0065] Example 9-1: 9% Metalaxyl·Enoxaflutole·Isotrione Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Isotrione 3%, Atlas G-5002L 2%, WINST 3682 2%, YUS-A51G 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0066] Preparation method: Same as in Example 2-1.

[0067] Example 9-2: 9% Metalaxyl·Enoxaflutole·Isotrione Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Isotrione 3%, Atlas G-5002L 2%, WINST 3682 2%, YUS-A51G 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0068] Preparation method: Same as in Example 2-1.

[0069] Example 10-1: 30% Metalaxyl·Enoxaflutole·Isotrione Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Isotrione 10%, Genapol PF 40 4%, Dispersogen ACP 120 4%, YUS-A51G 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0070] Preparation method: Same as in Example 3-1.

[0071] Example 10-2: 30% Metalaxyl·Enoxaflutole·Isotrione Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Enoxaflutole 10%, Isotrione 10%, Genapol PF 40 4%, Dispersogen ACP 120 4%, YUS-A51G 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up.

[0072] Preparation method: Same as in Example 3-1.

[0073] Example 11-1: A 2.5% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components in weight percentage: metalaxyl-mancozeb 1%, pyraclostrobin 0.5%, tebuconazole 1%, Genapol 10500 2%, DS7072%, DS569 1%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.25%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R12 15%, Deionized water to make up.

[0074] Preparation method: Same as in Example 1-1.

[0075] Example 11-2: A 2.5% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components in weight percentage: metalaxyl-mancozeb 1%, pyraclostrobin 0.5%, tebuconazole 1%, Genapol 10500 2%, DS7072%, DS569 1%, titanium dioxide 2%, magnesium aluminum silicate 1.0%, xanthan gum 0.25%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0076] Preparation method: Same as in Example 1-1.

[0077] Example 12-1: A 9% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components in weight percentage: metalaxyl-mancozeb 3%, pyraclostrobin 3%, tebuconazole 3%, Ethylan NS-500LQ 3%, SP-27001 2%. DS569 1%, magnesium aluminum silicate 0.8%, xanthan gum 0.2%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0078] Preparation method: Same as in Example 2-1.

[0079] Example 12-2: A 9% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 3%, pyraclostrobin 3%, tebuconazole 3%, Ethylan NS-500LQ 3%, SP-27001 2%. DS569 1%, titanium dioxide 2%, magnesium aluminum silicate 0.8%, xanthan gum 0.2%, ethylene glycol 5%, film-forming agent PVP / VA 645%, warning color JH-R12 15%, deionized water to make up.

[0080] Preparation method: Same as in Example 2-1.

[0081] Example 13-1: A 30% metalaxyl-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl 10%, pyraclostrobin 10%, tebuconazole 10%, TENSIOFIX 96DB08 4%, TENSIOFIX AMS303 3%. DS569 2%, magnesium aluminum silicate 0.5%, xanthan gum 0.1%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0082] Preparation method: Same as in Example 3-1.

[0083] Example 13-2: A 30% metalaxyl-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl 10%, pyraclostrobin 10%, tebuconazole 10%, TENSIOFIX 96DB08 4%, TENSIOFIX AMS303 3%. DS569 2%, titanium dioxide 2%, magnesium aluminum silicate 0.5%, xanthan gum 0.1%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R121 5%, deionized water to make up.

[0084] Preparation method: Same as in Example 3-1.

[0085] Example 14-1: 2.5% Metalaxyl·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Azoxystrobin 0.5%, Prothioconazole 1%, Genapol 10500 2%, SP-2700 12%, YUS-TXC 1%, Magnesium Aluminum Silicate 1.0%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0086] Preparation method: Same as in Example 1-1.

[0087] Example 14-2: 2.5% Metalaxyl-Methoxyfenozide·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Azoxystrobin 0.5%, Prothioconazole 1%, Genapol 10500 2%, SP-2700 12%, YUS-TXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 1.0%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 645%, Warning Color JH-R12 15%, and deionized water to make up.

[0088] Preparation method: Same as in Example 1-1.

[0089] Example 15-1: 9% Metalaxyl-Methoxystrobin·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Prothioconazole 3%, Synergen 848 3%, DOWFAX™ D30 52%, YUS-TXC 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0090] Preparation method: Same as in Example 2-1.

[0091] Example 15-2: 9% Metalaxyl-Methoxystrobin·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Prothioconazole 3%, Synergen 848 3%, DOWFAX™ D30 52%, YUS-TXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0092] Preparation method: Same as in Example 2-1.

[0093] Example 16-1: 30% Metalaxyl-Methoxystrobin·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Azoxystrobin 10%, Prothioconazole 10%, Pluronic PE6400 4%, ULTREASURF 7023A 3%, YUS-TXC 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0094] Preparation method: Same as in Example 3-1.

[0095] Example 16-2: 30% Metalaxyl-Methoxyfenozide·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl-Methoxyfenozide 10%, Azoxystrobin 10%, Prothioconazole 10%, Pluronic PE6400 4%, ULTREASURF 7023A 3%, YUS-TXC 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.1%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up.

[0096] Preparation method: Same as in Example 3-1.

[0097] Example 17-1: 2.5% Metalaxyl·Azoxystrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Azoxystrobin 0.5%, Imidacloprid 1%, ULTREASURF 8070 2%, SP-2700 12%, YUS-SXC 1%, Magnesium Aluminum Silicate 1.2%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0098] Preparation method: Same as in Example 1-1.

[0099] Example 17-2: 2.5% Metalaxyl-Methoxystrobin·Azoxystrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Azoxystrobin 0.5%, Imidacloprid 1%, ULTREASURF 8070 2%, SP-2700 12%, YUS-SXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 1.2%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0100] Preparation method: Same as in Example 1-1.

[0101] Example 18-1: 9% Metalaxyl-Methoxystrobin·Azoxystrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Imidacloprid 3%, YUS-5050PB 3%, SP-27001 2%, YUS-SXC 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up.

[0102] Preparation method: Same as in Example 2-1.

[0103] Example 18-2: 9% Metalaxyl-Methoxystrobin·Azoxystrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Imidacloprid 3%, YUS-5050PB 3%, SP-27001 2%, YUS-SXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up the difference.

[0104] Preparation method: Same as in Example 2-1.

[0105] Example 19-1: A 30% metalaxyl-mancozeb-pyraclostrobin-carbendazim seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, carbendazim 10%, PLURONIC PE6400 4%, DS5518 3%, YUS-SXC 2%, Magnesium aluminum silicate 0.4%, Xanthan gum 0.1%, Ethylene glycol 5%, Film-forming agent PVP / VA 645%, Warning color JH-R12 15%, Deionized water to make up.

[0106] Preparation method: Same as in Example 3-1.

[0107] Example 19-2: A 30% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, tebuconazole 10%, PLURONIC PE6400 4%, DS5518 3%, YUS-SXC 2%, titanium dioxide 2%, magnesium aluminum silicate 0.4%, xanthan gum 0.1%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0108] Preparation method: Same as in Example 3-1.

[0109] Example 20-1: A 2.5% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 1%, pyraclostrobin 0.5%, tebuconazole 1%, WINST5503 2%, DS569 1%, Agrilan 755 2%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.25%, Ethylene glycol 5%, Film-forming agent PVP / VA 645%, Warning color JH-R12 15%, Deionized water to make up.

[0110] Preparation method: Same as in Example 1-1.

[0111] Example 20-2: A 2.5% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 1%, pyraclostrobin 0.5%, tebuconazole 1%, WINST5503 2%, DS 569 1%, Agrilan 755 2%, Titanium dioxide 2%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.25%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R121 5%, Deionized water to make up.

[0112] Preparation method: Same as in Example 1-1.

[0113] Example 21-1: 9% Metalaxyl·Pyraclostrobin·Izoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Izoxystrobin 3%, Winst5503 3%, MORWET D425 1%, TENSIOFIX AMS303 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0114] Preparation method: Same as in Example 2-1.

[0115] Example 21-2: 9% Metalaxyl·Pyraclostrobin·Izoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Izoxystrobin 3%, Winst5503 3%, MORWET D425 1%, TENSIOFIX AMS303 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up the difference.

[0116] Preparation method: Same as in Example 2-1.

[0117] Example 22-1: A 30% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, tebuconazole 10%, YUS-5050PB 3%, DS5518 2%, DS569 2%, magnesium aluminum silicate 0.5%, xanthan gum 0.1%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0118] Preparation method: Same as in Example 3-1.

[0119] Example 22-2: A 30% metalaxyl-mancozeb-pyraclostrobin-tebuconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, tebuconazole 10%, YUS-5050PB 3%, DS5518 2%, DS569 2%, titanium dioxide 2%, magnesium aluminum silicate 0.5%, xanthan gum 0.1%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R121 5%, deionized water to make up.

[0120] Preparation method: Same as in Example 3-1.

[0121] Example 23-1: A 2.5% metalaxyl-pyraclostrobin-prothioconazole seed treatment suspension, comprising the following components by weight percentage: metalaxyl 1%, pyraclostrobin 0.5%, prothioconazole 1%, ULTREASURF 8070 2%, ACP 120 2%, SK-24N 1%, YUS-SXC 1%, magnesium aluminum silicate 1.0%, xanthan gum 0.25%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, and deionized water to make up the difference.

[0122] Preparation method: Same as in Example 1-1.

[0123] Example 23-2: 2.5% Metalaxyl·Pyraclostrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 1%, Pyraclostrobin 0.5%, Prothioconazole 1%, ULTREASURF 8070 2%, ACP 120 2%, SK-24N 1%, YUS-SXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 1.0%, Xanthan Gum 0.25%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0124] Preparation method: Same as in Example 1-1.

[0125] Example 24-1: 9% Metalaxyl·Pyraclostrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Prothioconazole 3%, DOWFSAXTM D865 3%, SP-27001 2%, SK-24N 1%, YUS-SXC 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up.

[0126] Preparation method: Same as in Example 2-1.

[0127] Example 24-2: 9% Metalaxyl·Pyraclostrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Prothioconazole 3%, DOWFSAXTM D865 3%, SP-27001 2%, SK-24N 1%, YUS-SXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up the difference.

[0128] Preparation method: Same as in Example 2-1.

[0129] Example 25-1: 30% Metalaxyl·Pyraclostrobin·Prothioconazole Seed Treatment Suspension Contains the following ingredients in weight percentage: Metalaxyl 10%, Pyraclostrobin 10%, Prothioconazole 10%, SD-208 4%, WINST3796 3%, Morwet D425 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.08%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, Deionized Water to make up.

[0130] Preparation method: Same as in Example 3-1.

[0131] Example 25-2: 30% Metalaxyl·Pyraclostrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 10%, Pyraclostrobin 10%, Prothioconazole 10%, SD-208 4%, WINST3796 3%, Morwet D425 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.08%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up.

[0132] Preparation method: Same as in Example 3-1.

[0133] Example 26-1: A 2.5% metalaxyl-mancozeb-pyraclostrobin-carbendazim seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 1%, pyraclostrobin 0.5%, carbendazim 1%, DOWFAX™ D865 2%, DS733 2%, YUS-TXC 1%, Magnesium aluminum silicate 1.0%, Xanthan gum 0.25%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R12 15%, Deionized water to make up.

[0134] Preparation method: Same as in Example 1-1.

[0135] Example 26-2: A 2.5% metalaxyl-M·pyraclostrobin·carbendazim seed treatment suspension, comprising the following components by weight percentage: metalaxyl 1%, pyraclostrobin 0.5%, carbendazim 1%, DOWFAX™ D865 2%, DS733 2%, YUS-TXC 1%, titanium dioxide 2%, magnesium aluminum silicate 1.0%, xanthan gum 0.25%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0136] Preparation method: Same as in Example 1-1.

[0137] Example 27-1: 9% Metalaxyl·Pyraclostrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Imidacloprid 3%, SD-208 3%, SD-816 2%, SP-3259 1%, YUS-A51G 1%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up the difference.

[0138] Preparation method: Same as in Example 2-1.

[0139] Example 27-2: 9% Metalaxyl·Pyraclostrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Imidacloprid 3%, SD-208 3%, SD-816 2%, SP-3259 1%, YUS-A51G 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up the difference.

[0140] Preparation method: Same as in Example 2-1.

[0141] Example 28-1: A 30% metalaxyl-mancozeb-pyraclostrobin-carbendazim seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, carbendazim 10%, YUS-5050PB 3%, DS5518 2%, Winst 1130L 2%, YUS-TXC 1%, Magnesium aluminum silicate 0.5%, Xanthan gum 0.05%, Ethylene glycol 5%, Film-forming agent PVP / VA64 5%, Warning color JH-R12 15%, Deionized water to make up.

[0142] Preparation method: Same as in Example 3-1.

[0143] Example 28-2: A 30% metalaxyl-mancozeb-pyraclostrobin-carbendazim seed treatment suspension, comprising the following components by weight percentage: metalaxyl-mancozeb 10%, pyraclostrobin 10%, carbendazim 10%, YUS-5050PB 3%, DS5518 2%, Winst 1130L 2%, YUS-TXC 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.5%, Xanthan Gum 0.05%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, Deionized Water to make up the difference.

[0144] Preparation method: Same as in Example 3-1.

[0145] Comparative Example 1: 9% Metalaxyl-M·Enoxaflutole·Syfop-R-methyl Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Syfop-R-methyl 3%, SK-33SC 2%, SP-SC29 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up the difference.

[0146] Preparation method: Same as in Example 2-1.

[0147] Comparative Example 2: 9% Metalaxyl-M·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Prothioconazole 3%, YUS-FS3000 3%, SK-335 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up the difference.

[0148] Preparation method: Same as in Example 2-1.

[0149] Comparative Example 3: 9% Metalaxyl-M·Enoxaflutole·Isotrione Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Enoxaflutole 3%, Isotrione 3%, SP-EW33530 3%, Morwet EFW 2%, SP-SC29 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA 645%, Warning Color JH-R12 15%, and deionized water to make up.

[0150] Preparation method: Same as in Example 2-1.

[0151] Comparative Example 4: 9% Metalaxyl-Azoxystrobin-Izoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl-Azoxystrobin 3%, Izoxystrobin 3%, Izoxystrobin 3%, SK-9457 3%, WINST 3791 3%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R121 5%, and deionized water to make up the difference.

[0152] Preparation method: Same as in Example 2-1.

[0153] Comparative Example 5: 9% Metalaxyl-Methoxystrobin·Azoxystrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Prothioconazole 3%, 2425 4%, DS505 3%, TERGITOLTM W600 1%, titanium dioxide 2%, magnesium aluminum silicate 0.8%, xanthan gum 0.19%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R12 15%, deionized water to make up.

[0154] Preparation method: Same as in Example 1-1.

[0155] Comparative Example 6: 9% Metalaxyl-Metazon·Azoxystrobin·Imidacloprid Seed Treatment Suspension, comprising the following components in weight percentage: Metalaxyl 3%, Azoxystrobin 3%, Imidacloprid 3%, Atlox 4913 2%, DS520 2%, titanium dioxide 2%, magnesium aluminum silicate 0.8%, xanthan gum 0.2%, ethylene glycol 5%, film-forming agent PVP / VA64 5%, warning color JH-R121 5%, deionized water to make up.

[0156] Preparation method: Same as in Example 2-1.

[0157] Comparative Example 7: 9% Metalaxyl-Methionate·Pyraclostrobin·Izoxystrobin Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl-Methionate 3%, Pyraclostrobin 3%, Izoxystrobin 3%, Soprophor SC 2%, WINST3791 3%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0158] Preparation method: Same as in Example 2-1.

[0159] Comparative Example 8: 9% Metalaxyl-Methionate·Pyraclostrobin·Prothioconazole Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl 3%, Pyraclostrobin 3%, Prothioconazole 3%, SK-34SC 3%, SP-EW33530 2%, Petro AA 1%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0160] Preparation method: Same as in Example 2-1.

[0161] Comparative Example 9: 9% Metalaxyl-Methionate·Pyraclostrobin·Imidacloprid Seed Treatment Suspension, comprising the following components by weight percentage: Metalaxyl-Methionate 3%, Pyraclostrobin 3%, Imidacloprid 3%, Agrilan 1015 3%, TENSIOFIX TSC 2%, Titanium Dioxide 2%, Magnesium Aluminum Silicate 0.8%, Xanthan Gum 0.2%, Ethylene Glycol 5%, Film-forming Agent PVP / VA64 5%, Warning Color JH-R12 15%, and deionized water to make up.

[0162] Preparation method: Same as in Example 2-1.

[0163] In the above embodiments, the difference between Embodiment 1-1 and Embodiment 1-2 is that Embodiment 1-2 adds a grinding aid to Embodiment 1-1, and the other paired embodiments are the same; Comparative Embodiment 1 is a comparative embodiment of Embodiments 1-1 to 4-2, and the difference between the corresponding comparative embodiment and the embodiment is that the wetting and dispersing agent combination described in this invention is not used; Comparative Embodiment 2 is a comparative embodiment of Embodiments 5-1 to 7-2, and the difference is the same as before, and the differences between the subsequent embodiments and comparative embodiments are as described above.

[0164] The results of the material discharge status and milling time in the above embodiments are shown in Table 1 below:

[0165] Table 1. Feed discharge status and milling time in different embodiments

[0166]

[0167]

[0168] According to the testing standards for seed treatment suspensions, the content, suspension rate, viscosity and other properties of the seed treatment suspensions prepared in Examples 1-1 to 28-2 and Comparative Examples 1 to 10 were tested respectively. The test results are shown in Table 2.

[0169] Table 2. Performance test results of the samples in the examples.

[0170]

[0171]

[0172]

[0173] As can be seen from Table 1, the material discharge state and grinding time of different embodiments, the embodiments with added grinding aids accelerated the grinding time. However, in Comparative Examples 1-9, without the use of the wetting and dispersing agent combination described in this invention, the grinding beads were covered with viscous agglomerated materials to varying degrees after grinding, and normal grinding material could not be obtained.

[0174] According to the test results in Table 2, the contents of the three components in the sample prepared by the present invention are significantly lower than the theoretical amount. Due to the presence of agglomerated particles in the sample, the suspension rate is not up to standard, and the viscosity of the sample increases significantly after heat storage.

[0175] Indoor bioactivity test

[0176] Test reagents: Metalaxyl technical grade, tebufenozide technical grade, cymoxanil technical grade, metalaxyl technical grade

[0177] Test pathogens: Rhizoctonia solani and Gibberella zeae.

[0178] Experimental treatment method: The mycelial growth rate method was used. Under aseptic conditions, the drug solution was prepared at the set concentration. A blank control without the drug was also set for each tested pathogen. Each treatment was repeated three times. The prepared culture medium was cooled to 50-60℃, and a quantitative amount of the drug was added at the set concentration to prepare plates containing different amounts of the drug. After the plates had fully cooled, 0.5 cm diameter mycelial discs of the tested pathogens were inoculated and placed in a humidity incubator (20-28℃). The results were collected after 1-7 days. During the investigation, the colony diameter of the tested pathogens in each treatment was measured and recorded.

[0179] Method for calculating antibacterial rate:

[0180] Inhibition rate (%) = [(Control colony diameter - Treated colony diameter) / (Control colony diameter)] × 100%

[0181] The drug concentration is converted into a logarithm (x), and the inhibition rate is converted into a probability value (y). Based on the linear relationship between x and y, the toxicity regression curve equation y = a + bx, the correlation coefficient (r), and the effective inhibition median concentration (EC50) are obtained.

[0182] Table 3. Comparison of the activity of formulations of metalaxyl-methyl, tebuconazole, and cyproconazole (Rhizoctonia solani)

[0183]

[0184] Table 4. Comparison of the activity of formulations of metalaxyl-methyl, tebuconazole, and cyproconazole (Fusarium graminearum)

[0185]

[0186] Tables 3 and 4 show that 4.2% metalaxyl + tebuconazole + cymoxanil (1.4 + 0.5 + 2.3) has an EC50 of 1,000 against Rhizoctonia solani and Fusarium graminearum. 50 The EC50 values ​​(mg / L) were 0.0783 and 0.0620, respectively, and their activity was significantly higher than that of the control formulation 4.23% metalaxyl + tebuconazole (1.88 + 2.35). 50 The (mg / L) values ​​were 0.3560 and 0.0901, and the combination of the three original drugs showed good indoor biological activity.

[0187] In summary, the suspending agent of this invention, when used in combination with suitable wetting and dispersing agents, effectively disperses the three active ingredients, improving the problems of liquid active ingredients being difficult to disperse and adhere to milling equipment and solid active ingredients, resulting in a uniformly flowing liquid. The block polyether adjuvant in the wetting and dispersing agent has an amphiphilic structure with EO and PO chains, enabling it to be directionally adsorbed at the oil-water interface, significantly reducing the interfacial tension between the oily active ingredient and the aqueous phase. By selecting block polyether wetting and dispersing agents with appropriate EO and PO ratios, suitable hydrophilic and lipophilic properties promote the dispersion of the oil phase into fine droplets, effectively solving the problem of metalaxyl being difficult to disperse in water. The hydrophobic PO chains are firmly anchored to the surface of the oil phase droplets, while the hydrophilic EO chains extend into the aqueous phase, forming a three-dimensional "protective layer." This steric hindrance effectively prevents droplet aggregation during collisions, avoiding metalaxyl encapsulating solid active ingredient particles and improving the problem of metalaxyl adhering to solid active ingredients, thus enabling the effective dispersion of both metalaxyl and the other two solid active ingredients. Meanwhile, the sulfonate anionic surfactants, with their hydrophilic sulfonate groups and hydrophobic hydrocarbon groups, form a hydrophilic adsorption layer on the surface of the metalaxyl technical particles, isolating the oily technical particles from each other and preventing them from approaching and agglomerating, thus maintaining the stable dispersion of the oily technical in the aqueous system. The dual isolation effect of these two types of adjuvants also reduces unnecessary interactions between the oily technical and other components, and they can be firmly adsorbed onto the surface of the technical particles at different temperatures, preventing the aggregation and agglomeration of technical droplets and particles, helping to maintain the chemical and physical stability of the system and control the increase in viscosity after heat storage. Furthermore, the carboxyl groups in the polycarboxylate adjuvant molecules can be firmly adsorbed onto the surface of solid technical particles through electrostatic interactions, forming a stable adsorption layer; the hydrophilic segments extend into the aqueous phase, creating a steric hindrance effect and preventing particle agglomeration. As shown in Table 2, the combination of the above-mentioned nonionic and anionic adjuvants can effectively inhibit the growth and agglomeration of active ingredient droplets and particles after heat storage, improving the viscosity increase problem.

[0188] In addition, after adding the grinding aid to the system of the present invention, the grinding aid can act as a "secondary grinding medium" to assist the grinding beads in impacting and shearing large particles, thereby accelerating the particle crushing efficiency; its fine particles can fill the spaces between the particles to be ground, reducing direct adhesion between particles, avoiding particle aggregation during the grinding process, reducing grinding time, and effectively improving grinding efficiency.

[0189] As can be clearly seen from the foregoing embodiments, by screening and rationally proportioning wetting and dispersing agents, grinding aids, and other additives, the problems of poor dispersion of liquid metalaxyl-mancozeb and adhesion of solid metalaxyl to sand milling equipment are effectively solved, greatly reducing sand milling time and improving sand milling efficiency. The seed treatment suspension of this invention has good physical stability and suspension performance, maintaining suitable viscosity even under high temperature conditions, ensuring long-term storage and use effectiveness, and maintaining the corresponding preventive effect.

Claims

1. A seed treatment suspension concentrate comprising metalaxyl-M, characterized in that: The seed treatment suspension agent contains, by weight percentage, 1.5-60% of active ingredient, 1-20% of wet dispersant, 0-5% of grinding aid, 1-10% of anti-freezing agent, 0.01-2% of thickening agent, 1-10% of film forming agent, 5-20% of warning color, and deionized water.

2. The seed treatment suspension concentrate containing monomeymycin according to claim 1, characterized in that: The active ingredient is metalaxyl-M, compound A and compound B; wherein compound A is a methoxy acrylate fungicide, and compound B is a triazole fungicide.

3. The seed treatment suspension concentrate containing per-metamitron according to claim 2, characterized by: The compound A is selected from dimoxystrobin (A1), azoxystrobin (A2) or pyraclostrobin (A3); and the compound B is selected from ipconazole (B1), prothioconazole (B2) or metconazole (B3).

4. The seed treatment suspension concentrate containing per-metamitron according to any one of claims 1 to 3, characterized in that: The seed treatment suspension agent contains, by weight percentage, 1-10% of metalaxyl-M, 0.5-10% of compound A, 1-10% of compound B, 3-15% of wet dispersant, 0.5-5% of grinding aid, 4-8% of anti-freezing agent, 0.1-2% of thickening agent, 3-6% of film forming agent, 10-15% of warning color, and deionized water.

5. The seed treatment suspension concentrate containing per-metamitron according to claim 1, characterized by: The wet dispersant is a block polyether, a polycarboxylate and a sulfonate; wherein the block polyether, the polycarboxylate and the sulfonate account for 1-8%, 1-5% and 1-4% of the weight of the wet dispersant, respectively.

6. The seed treatment suspension concentrate containing per-metamitron according to claim 5, characterized by: The block polyether, the polycarboxylate and the sulfonate in the wet dispersant account for 2-5%, 2-4% and 1-3% of the weight of the wet dispersant, respectively.

7. The seed treatment suspension concentrate containing per-metamitron according to claim 1, characterized by: The grinding aid is one or more of titanium white, white carbon black, organic bentonite and fumed silica.

8. The seed treatment suspension concentrate containing metalaxyl-M according to claim 1, characterized in that, The seed treatment suspension agent is applied in coating of crop seeds.

9. The seed treatment suspension concentrate containing per-metamitron according to claim 8, characterized by, The seed treatment suspension agent is applied in the prevention and treatment of fungal diseases in coating of crop seeds.

Images